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Urinary endothelin and renal vasoconstriction with cyclosporine or
FK506 after liver transplantation. Transplant immunosuppression using
either cyclosporine (C5A) or FK506 leads to renal vasoconstriction. To
examine the role of endothelin (ET) in this process, we measured plasma
and urinary FT before and at intervals for two years after liver transplan-
tation. Urinary prostacyclin (as 6-keto-PG-Fln), thromboxane, glomeru-
lar filtration rate and renal plasma flow were also measured. Forty-four
patients were treated with CsA-based regimens and 31 patients with
FK506-based regimens. Prednisone doses after one year were lower with
FK506 (5.5 0.5 vs. 10.5 0.5 mg/day) by study design. Circulating
plasma ET remained above normal, but not different from pre-transpiant
levels. Urinary ET was elevated before transplant (24.6 3.4 nglday vs.
normal 16 1.5 ng/day, P < 0.05) and rose further after transplantation
(48.5 13 nglday, P < 0.05), remaining elevated for two years. 6-keto-
PG-Fin fell from 2567 338 ng/day to subnormal levels and remained
suppressed (1158 128 ng/day, P <0.01). Over the same period GFR fell(84 3 mI/mm to 60 3 mI/mm, P < 0.01) and renal vascular resistance
index rose (11,119 561 to 23,279 1692 d s cm5 m, P < 0.01).
Similar changes were observed both with CsA and FK5OÔ-based immu-
nosuppression. No changes in ET were attributable to dihydropyridine
calcium channel blockers. These results demonstrate that urinary ET
changes independently from plasma ET after transplantation. Elevated
ET and suppression of endothelium-derived prostacyclin persist with
intense renal vasoconstriction for at least two years after transplant.
Cyclosporine-based immunosuppression for organ transplanta-
tion regularly leads to widespread vasoconstriction, which mani-
fests primarily as nephrotoxicity and hypertension. Disturbances
in vascular tone develop in most vascular beds, but are particularly
intense within the kidney. While these commonly have been
attributed to the use of cyclosporine A (C5A) [11, similar changes
in the renal vasculature are observed with a structurally unrelated
immunosuppressive agent, FK506 [2, 3]. The mechanisms under-
lying increased vascular tone in human transplant recipients are
not fully understood.
Endothelin (ET) is a potent vasoconstrictor peptide originally
identified from vascular endothelial cells and is considered likely
a likely candidate to participate in post-transplant vasoconstric-
tion. ET mediates experimental CsA-induced vasoconstriction, at
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least during short-term studies [4]. Circulating ET rises abruptly
after intravenous administration of CsA in rats [5] and incubation
of endothelial cells with CsA induces endothelin release [61. Some
studies indicate that immediate hemodynamic effects of CsA may
be blocked by antibodies to ET [5]or by ETa receptor antagonists,
such as BQ123 [7], However, these effects are transient and
studies with other ET antagonists do not universally support these
conclusions [8]. Administration of dihydropyridine calcium chan-
nel blockers, such as nifedipine, reduces both urinary excretion of
ET and the renal effects of CsA in the rat [9]. The relevance of
such experimental studies to human disease is limited by the fact
that CsA rarely ibads to sustained hypertension in animals, and
that results of mechanistic studies with CsA in animals often differ
from results of human studies, as we have reviewed [4].
The role of ET in human transplant recipients after transplan-
tation is less certain. Circulating plasma levels rise immediately
after transplantation [10] but fall to pre-transplant levels by one
month [11]. Some reports indicate that plasma ET levels are
increased later [12] while others do not [13, 14]. It is uncertain
whether measurement of plasma ET levels accurately reflects
local ET production and activity. Studies in renal allograft recip-
ients indicate that urinary ET rises transiently after each CsA
dose, without changes in circulating plasma levels [13]. Few data
address late changes in ET at the reduced levels of CsA and
steroids during long-term immunosuppression after transplant,
that is, two years and beyond. Virtually no human data are
available regarding changes in ET for patients treated with
FK506-based immunosuppression.
Our previous studies indicate that urinary excretion of another
endothelium-derived vasoactive substance, prostacyclin, is sup-
pressed below normal during the early period after liver trans-
plantation in humans with either CsA or FK506-based regimens
[3, Ii], results which are supported by several other studies
[15—171. Liver transplant recipients offer the advantage of allow-
ing study of renal and cardiovascular events in a setting in which
neither the kidney or heart themselves are allografts.
The present studies were undertaken to characterize changes in
urinary and circulating endothelin for two years after liver trans-
plantation in patients treated with either CsA- or FK.506-based
immunosuppressive regimens. Urinary excretion of prostacyclin
and thromboxane metabolites were also determined. It was our
hypothesis that transplant immunosuppression with either CsA or
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Age
M/F
Diagnoses
Cholestatic disease
Primary biliary cirrhosis
Primary/secondary
scierosing cholangitis
Parenchymal liver disease
Chronic active hepatitis
Post-hepatic cirrhosis
Cirrhosis-alcohol
Other: aipha-1-antitripsin
Budd-chiari, etc.
FKSO6 may induce generalized vascular endothelial injury leading
to impaired prostacyclin production and enhanced release of
endothelin over a sustained time period.
Methods
Study subjects
Forty-four liver transplant recipients between January 1990 and
February 1992 whose immunosuppression was based upon CsA
were studied. The distribution of liver diseases leading to trans-
plantation is summarized in Table 1. Patients were excluded if
they were unable complete pre-transplant studies, for example, if
they were obtunded with fulminant hepatic failure or had hepa-
torenal syndrome. Before transplant surgery, patients were admit-
ted to the General Clinical Research Center for renal, hormonal
and hemodynamic measurements during ingestion of a diet
containing 100 mEq Na and 80 mEq K as previously described
[11]. An additional 31 patients whose immunosuppression was
based upon FK5Ofi and prednisorie as part of a prospective
multicenter trial were studied in similar fashion. After transplan-
tation and hospital discharge, these patients were followed in the
transplant hypertension unit during the first month, then during
scheduled return visits at four, twelve and twenty-four months.
Body weights, medication doses, and serum chemistry values were
recorded. Twenty-four hour collections for urine sodium, creati-
nine and prostaglandin excretion were obtained. Renal hemody-
namic studies were performed as described below. The proce-
dures for this study were approved by the institutional review
board of the Mayo Foundation.
Post-transplant immunosuppresion in the CsA group consisted
of cyclosporine (CsA: 2 to 3 mg/kg i.v./day followed by oral doses
to maintain trough levels between 250 to 400 ng/ml during the first
month, then 150 to 250 ng/ml thereafter, as measured by whole
blood HPLC); azathioprine (2 mg/kg) and prednisone (200 mg/d
tapering to 20 mg/day in the first month and to 10 mg/day after the
second month) as previously described [18]. The FK506 group
were treated with 0.15 mg/kg/day i.v initially, followed by oral
doses of 0.15 mg/kg/day, as previously described. Prednisone
doses were 100 mg/day tapering to 20 mg/day by day 5 and 5
mg/day by the second month. Doses of FK506 were reduced in
cases of toxicity. Trough levels were maintained between 0.5 and
8 ng/ml, as measured by ELISA with liquid-liquid extraction [19].
Actual doses used of CsA, FKSO6 and prednisone at each time
point are summarized in Table 2.
Calcium channel blockade
To examine the effects of dihydropyridine calcium channel
blockers (CCBs) upon endothelin and urinary eicosanoids, CsA-
treated patients were divided for separate analysis into those
treated with CCBs, primarily nifedipine XL, and those not treated
with CCBs, after one year.
Hormonal measurements
Plasma and urinary endothelin was measured by a sensitive
radioimmunoassay previously described [21]. Blood samples were
placed into chilled tubes containing potassium EDTA, placed
immediately on ice until being centrifuged at 4°C. Plasma was
separated and stored at —20°C. Before radioimmunoassay,
plasma was acidified with 0.5% triflouroacetic acid. Extraction
was performed with C8 Bond Elut cartridge, washed with 4 ml of
methanol and 4 ml of water. Endothelin was then eluted with 2 ml
of 90% methanol in 1% trifiouracetic acid, then dried and
reconstituted for radioimmunoassay. Recovery by this procedure
is 81%.
Synthetic peptide ET-1 (21 AA, Peninsula Laboratories, Bel-
mont, CA, USA) was used to prepare standard and tracer. Rabbit
antiserum to endothelin (RAS-6901, Peninsula Laboratories) was
incubated with standard and labeled for 24 hours at 4°C. The
standard curve was constructed by serial dilutions of synthetic
peptide from 126 pg/100 iii to 0.5 pg/100 microliter. The level of
delectability of the assay is 0.5 pg/ml with a range of 0.5 to 400
pg/mi. Inter-assay and intra-assay variations are 9.2 1.4% and
2.3 1.4%, respectively. Cross reactivity to endothelin-2 is less
than 5%, endothelin-3 less than 7% and big endothelin less than
37%.
Urinary eicosanoids
Excretion of 6-keto-PG-Fla (as the stable metabolite of pros-
tacyclin) and thromboxane B2 (as the stable metabolite of throm-
boxane A2) were measured by radioimmunoassay as previously
described [11]. Urine was collected on ice and frozen until
extracted. Aliquots of 0.5 ml were brought to 2 ml with phosphate
buffer. A Fisher C-18 octadecylsilyl silica column was prewashed
with absolute methanol, after which the urine sample was applied.
Serial passages of solvent mixtures of methanol, petroleum ether
and ethyl acetate were applied for separation, after which the
sample was dried under nitrogen gas at 30°C, then stored at
—20°C until radioimmunoassay.
The immunoassays were performed using 6-keto-PG-Fla and
thromboxane B2 standards and iodinated rabbit antibody to
thromboxane obtained from Dupont Research Products (NEK-
024) and (NEK-025). Precipitation of bound prostaglandins and
antibody was achieved in a solution of 16% polyethylene glycol
and 0.05% sodium azide in 50 mii phosphate buffer, pH 6.8, after
which samples were counted in a gamma counter. Recovery by
this method of added samples exceeds 93%. Inter-assay variability
and intra-assay variability at the ranges normally encountered in
human urine are 7% and 5.5%, respectively. Cross-reactivity of
the antibody for each prostaglandin has been determined to be
less than 0.01% 22j.
Table 1. Pre-transplant diagnoses
CsA group(N = 44)
For comparison purposes, normal values for renal and hor-
FK506 group monal measurements were obtained from subjects free of medical(N = 31) conditions participating in the Rochester Family Heart Study
during conditions of known sodium intake as reported [20].49 1.8 years
18/26
27 (61.4%)
17
10
17 (38.6%)
4
6
4
3
52 2.2
15/16
11(36%)
2
9
20 (64%)
7
4
2
7
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Table 2A. Liver function, immunosuppression, and clinical data after liver transplantation
CsA group (N = 44)
Pre-treatment 1 Month 4 Months 12 Months 24 Months
Bilirubin mg/dl 4.9 1.5 3.34 0.96 0.90 0.07 1.03 0.10 0.9Q 0.07
Albumin gIdi 2.7 0.07a 3.23 0.06 4.02 0.07 4.10 0.04 4.04 0.06
AST mIU/liter 146 l9 48 8 34 3 41 6 40 6
Pred dose mg/day N/A 26 1b 15.7 0.4" 10.5 0.2" 9.9 0.1"
CsA dose mg/day N/A 605 31 482 30 320 15 295 15
CsA level ng/dl N/A 288 19 197 11 148 6 128 9
Creatinine mg/dl 0.92 0.04a 0.98 0.05" 1.39 0.06 1.44 0.05 1.45 0.04
HTN % N/A 61%b 788%b 73%b 727%
24-Hr UNaV mEq/dl 151 52 173 14 111 9 118 9 120 9
Plasma renin activity ng/ml/ml/hour 8.5 1.4 1.7 0.38 2.1 0.34 2.05 0.31 2.49 0.37
Table 2B. Liver function and immunosuppression after liver transplants
FK506 group (N = 31)
Pre-transplant 1 Month 4 Months 12 Months 24 Months
Bilirubin mg/dl 6.9 1.5' 0.8 0.07 0.7 0.1 0.6 0.1 00.8 0.14
Albumin g/dl 2.7 0.la 3.19 0.08 4.13 0.07 4.23 0.11 04.2 0.07
AST miUlliter 96 14 37 6 63 15 37 4 32.0 4
Pred dose mg/day N/A 23.8 7 6 0.6 5.5 0.5 6.7 0.8
FK506 dose mg/day N/A 10.4 1.1 10.0 0.9 9 1.1 7.6 1.0
FK506 level ng/dl N/A 6.1 0.4 6.7 1.3 6.6 6 7.6 1.0
Creatinine mg/dl 1.02 0.07a 1.45 0.08 1.52 0.08 1.6 0.08 1.63 0.2
HTN % N/A 22.7% 31.3% 37.5% 53.8%
24-Hr UNaV mEq/liter 126 29 107 14 107 11 94 13 100 20
Plasma renin activity ng/ml/ml/hr 10.3 2.9a 2.66 0.6 1.7 0.5 1.5 0.9 1.6 0.5
Data are mean SEM unless indicated. NA is not applicable.
'P < 0.01 vs. 1 month and later
bP < 0.05 vs. FK506 group
Renal hemodynamic studies
Measurements of glomerular filtration rate and effective renal
plasma flow (ERPF) were performed using intravenous infusion
of 125-lothalamate and para-aminohippurate (PAH) over three
timed collection periods as previously described [11]. Renal blood
flow was calculated as ERPF/(1-hematocrit). Arterial blood pres-
sures were recorded by an automated oscillometric sphygmoma-
nometer at five-minute intervals (Accutorr., Datascope, Paramus,
NJ, USA) Renal vascular resistance index was calculated using
mean arterial pressure (MAP: diastolic pressure plus [systolic
minus diastolic pressurel/3) expressed as ((MAP)/renal blood flow
[expressed as liter/min/1.73 m2) * 80 d sec cm5 - m2.
Statistical methods
Data for each visit were recorded in a computer database using
CLINFO. Statistical analysis was undertaken using SYSTAT.
Data were expressed as mean SEM unless otherwise indicated.
Comparison between values at different time intervals was per-
formed by analysis of variance and repeated measures analysis of
variance, as appropriate. Specific comparisons were then per-
formed using Dunnet's test or Scheffe's test. Comparison between
groups was undertaken using analysis of variance or non-paramet-
ric (Wilcoxon rank sum) methods as appropriate [23].
Results
Clinical and biochemical features
Age, pre-transplant diagnosis and sex distribution for both CsA
and FK506 groups are summarized in Table 1. Cholestatic liver
disease (61%) was the largest single indication for liver transplan-
tation in the CsA group while the FK506 group tended to have
more patients with parenchymal liver disease (64%). Doses of
immunosuppressive medications and values for bilirubin, aspar-
tate transaminase (AST) and albumin are shown in Table 2 for
time points before and after transplantation for two years. During
this period mean values for bilirubin fell to normal (CsA: 4.9 1.5
mg/dl to 0.9 0.07, P < 0.01) and albumin rose (2.7 0.07 to 4,04
0.06 g/dl, P < 0.01). Similar changes of the same magnitude
were observed in patients treated with FK506.
Doses of immunosuppressive medications were reduced pro-
gressively during the two-year follow-up period (Table 2). Mean
trough blood levels of CsA doses were 128 9 nglml by two years.
FK506 trough levels were near 6.5 ng/ml after the first month. By
one year after transplant, mean daily prednisone doses were 11
2 mg/day in the CsA group and 6 1 mg/day (P < 0.01) in the
FK506 group and remained at these levels thereafter. It should be
emphasized that these doses were pre-selected by protocol design.
Kidney function is illustrated in Figure 1. Glomerular filtration
rate fell from 84 3 to 60 3 mI/mm (P < 0.01) in CsA-treated
patients by one year and remained low thereafter. The FKSO6-
treated group fell from 92 7 to 56 5 mI/mm (P < 0.01) over
the same time period. These decrements were associated with
intense renal vasoconstriction in all transplant patients as re-
flected by a rise in renal vascular resistance index (RVRI, Fig. 1B)
in the CsA group at one year, from 11,119 561 to 23,279 1,692
s - cm5 - m2 (P < 0.01). RVRI in the FKSO6 group rose from
12,275 1,506 to 25,164 2,584 d s -cm5 - m2 (P < 0.01).
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Fig. 1. A. Glomendar filtration rate measured by
iothalamate clearance in 44 CsA -treated subjects() and 31 FK506-treated subjects (El) before
liver transplantation and during one and two year
follow-up evaluations. GFR fell after
transplantation and remained low throughout
this period. Shaded zone represents data from
normal subjects obtained under similar dietary
conditions using the same methods, as reported
[201. B. Renal vascular resistance index (RVRI)
as determined from mean arterial blood
pressure and renal blood flow determined by
para-aminohippurate clearance (see text). The
fall in GFR was associated with sustained renal
vasoconstriction in both CsA and FK506
treated groups over a two year period after
liver transplantation. < 0.01 vs.
pretransplant; tP < 0.01 vs. normal subjects.
The prevalence of sustained clinical hypertension (defined as
blood pressure > 140/90 mm Hg at the current time point or
having led to administration of antihypertensive medication) at
each time point is shown in Table 2. Hypertension in CsA-treated
patients ranged between 74 and 83% after the first month. By
contrast, the percentage of FK506-treated patients developing
clinical hypertension was lower throughout the first year (for
example, at 4 months 28% vs. 78%, P < 0.01). However, the
proportion of FKSOÔ-treated patients with clinical hypertension
rose by the end of the second year after transplant and did not
differ from the CsA group (54% vs. 73%, NS).
Endothelin csA
-group
Average circulating levels of endothelin (ET) were above
normal before transplantation and remained elevated during the
entire two years after transplantation, as shown in Figure 2A. At
two years, ET levels remained above normal [CsA: 16.5 1.6
pg/mi vs. 7.07 0.07 pg/mI (normals), P < 0.01. Pre-transpiant
urinary endothelin (UET) was slightly above that of normal
subjects (CsA: 24.6 3.4 nglday vs. 16 1.5 ng/day, P < 0.05). In
contrast to circulating levels, UET rose further after liver trans-
plantation to 48.5 13 nglday by one month (P < 0.05) and
remained elevated throughout the two year interval (Fig. 2B).
Hence, urinary ET rose at least twofold after transplantation
while circulating ET levels were unchanged.
FK506 group
Circulating ET remained elevated (17.8 1.4 pg/mI vs. normal
7.07 0.07 pg/mi, P < 0.01) both before transplant and through-
out the two year period (24 months 23 3 pg/mi). Urinary ET
rose in parallel fashion to the CsA group, from 35 5 ng/day to
61 10 ng/day after one month, remaining elevated thereafter
(Fig. 2B). When values for all subjects were considered, RVRI
was correlated with urinary excretion of ET (r = 0.42, P < 0.00 1).
Eicosanoids: CsA group
Urinary excretion of the prostacyciin metaboiite, 6-keto-PG-
Fin, and the thromboxane A2 metabolite, Thromboxane B2, are
illustrated in Figure 3. 6-Keto levels fell from 2567 338 to 1158
128 ng/day (P < 0.01) at two years. Levels were suppressed
below normal at all time points after the first month. In contrast,
thromboxane B2 excretion was elevated before transplantation
A
Normal
30,000
25.000
20,000
15.000
10,000
5,000
0
Pretransplant 12 months 24 months
t
B
Pretransplant 12 months 24 months
Normal
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differences were apparent between groups regarding circulating
plasma ET, urinary ET or 6-keto excretion. Glomerular filtration
rate was not different between groups receiving calcium channel
blocking agents or not.
Other vasoactive hormones
Plasma renin activity fell from 8.5 1.4 to 1.7
.38 ng/ml/hr
(P < 0.01) by one month. Renin remained below pretransplant
levels during subsequent measurements as shown in Table 2.
Atrial natriuretic peptide (ANP) fell gradually from 50.9 13
ngldl to 18.8 2.9 by four months and remained near normal
levels thereafter. Urinary sodium excretion at the time of these
measurements is summarized in Table 2.
Discussion
Fig. 2. A. Circulating endothelin levels before and after liver transplantation
in patients treated with either GsA (•) orFK506-based () immunosuppres-
sion. Although mean values remained above normal, they were unchanged
from pie-transplant levels and did not rise further. B. Urinary endothelin
(UET) excretion before and after liver transplantation. UET rose twofold
and remained elevated throughout the two.year study period in both CsA() and FK506 (LI) treated subjects. Elevated UET levels were associated
with elevated renal vascular resistance. *p < 0.01 vs. pretransplant; tP <
0.01 vs. normal subjects.
3296 331 versus normal (1224 200 nglday, P < 0.01) and fell
to normal levels (such as 1411 113 nglday at two years).
FK506 group
Urinary 6-keto-PG-Fla fell from 2382 351 ng/day to 676
78 ng/day at two years (P < 0.01 vs. both pre-transplant and CsA
at this point). Similarly, TBX2 levels fell from 3759 ng/day to 843
69 ng/day (P < 0.01). These levels remained suppressed
throughout the two-year follow-up period. A modest negative
correlation was apparent between 6-keto-PG-Fla and RVRI (r
—0.28, P < 0.001).
Effects of dihydropyridine calcium channel blocking agents
Summarized in Table 3 are endothelin and eicosanoid results in
CsA-treated and FK506-treated patients treated with or without
calcium channel blocking agents, principally nifedipine XL. No
These studies demonstrate development of sustained renal
vasoconstriction with disturbances of both endothelin and pros-
tacyclin from the kidney for two years after liver transplantation
with either CsA or FK506. Although circulating ET remained
above normal, decrements in renal blood flow were associated
more closely with elevation of urinary ET together with suppres-
sion of the vasodilatory prostaglandin, prostacyclin. The rise in
urinary ET occurred independently of circulating ET levels. Our
results establish that post-transplant renal vasoconstriction—in
kidneys not themselves allografts—was characterized by sustained
endothelial disturbances. Both immunosuppressive regimens af-
fected the renal vasculature for at least two years.
Our results extend previous observations made after renal
transplantation. Despite normal circulating ET levels, Perico et al
observed transient daily surges in urinary ET excretion after each
dose of CsA six months after transplant [13]. These and other
studies of the fate of injected endothelin indicate that urinary ET
is derived primarily from the kidney and does not reflect filtration
of circulating ET. Our initial studies demonstrated a transient rise
in circulating ET during the first week after liver transplantation,
even before the administration of CsA [10, 11]. As reported here,
average circulating ET levels thereafter did not differ from those
before transplantation and did not predict changes in either
systemic or renal hemodynamics. These data are consistent with
the concept that circulating ET represents an imprecise marker of
ET release, which appears to be directed primarily toward vascu-
lar smooth muscle cells, rather than into the vessel lumen [24, 25].
An alternative possibility, however, is that the same levels of
circulating ET may exert magnified effects in the post-transplant
milieu. Several studies indicate that the vasoactive effects of ET
are normally countered by vasodilatosy mechanisms, such as by
prostacyclin [26j or by endothelium-derived nitric oxide (EDNO)
[26, 271. Conditions under which either (or both) of these systems
are impaired lead to amplification of vasoconstriction mediated by
ET, even at normally subpressor levels.
The close similarity between renal and hormonal effects pro-
duced by CsA and FK506 warrants comment. These agents are
structurally unrelated and bind to different cellular receptors, but
induce closely related intracellular immunosuppressive actions
within t-cells [28, 291. Immunosuppression depends upon intra-
cellular signals requiring translocation of intracellular calcium, a
feature which is shared with vascular smooth muscle. Efforts to
dissociate immunosuppressive properties of these agents from
their ability to both penetrate cell membranes and alter calcium
localization thus far have had little success. It appears likely that
A
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Fig. 3. Urinaiy eicosanoids before and after liver transplantation. A. Pros-
tacyclin (as the metabolite 6-keto-PG-Fla) fell to levels below those of
normal subjects and remained suppressed throughout the two years after
transplantation. This effect was greatest in FK506 treated patients. B.
Thromboxane B2, which was elevated in subjects with end-stage liver
disease before transplant, fell to normal levels in both groups. Symbols
are: () CsA; (L) FK506. *p < 0.01 vs. pretransplant; tP < 0.01 vs.
normal subjects.
vascular effects are related closely to immunosuppressive proper-
ties of this class of compounds. Hence, disturbances of vascular
regulation are likely to develop whenever they are employed. Our
results suggest that altered vascular endothelial function related
to release of prostacyclin and endothelin may participate in these
effects, at least within the kidney.
It is of interest, however, that the susceptibility of particular
vascular beds is non-homogeneous, which may account for differ-
ing incidence of clinical hypertension, as we have previously noted
[31. The fact that FK506-based regimens induced similar changes
in UET and renal vasoconstriction, with less systemic vasocon-
striction and hypertension during the first year, provides further
support that de novo hypertension after transplantation may be
not be related to renal mechanisms alone [4, 301. Differences in
steroid doses between CsA and FK506 treated subjects in these
studies may be an important factor in the development of
hypertension early after transplantation. The late rise in blood
pressures in FK506-treated patients is noteworthy, however, and
suggests that different mechanisms regulating blood pressure may
apply at different time points after transplantation.
Most importantly, our results establish that renal endothelin
and prostacyclin excretion are disturbed after liver transplantation
without direct manipulation of the kidney. These changes devel-
oped within a month after transplant and persisted indefinitely.
Unlike studies in experimental animals, several human studies
indicate that prostacyclin is suppressed during CsA administration
[4]. We previously demonstrated this effect in the first several
weeks after transplant during which time renal vasoconstriction
and loss of GFR develops, despite rising arterial pressures and
normalization of previously highly active renin-angiotensin system
[11]. FK506 produces a similar hormonal and renal profile early
after transplantation [31. Results from the present study indicate
that urinary endothelin increased simultaneously with the sup-
rn of prostacyclin. Whether local release of ET caused the
'ed changes in prostacyclin, or vice versa, cannot be estab-
with the present data. Nonetheless, these combined effects
t the renal vasculature to multiple hormonal disturbances
rig vasoconstriction. The presence of multiple simultaneous
ances in the renal vasculature may explain the limited
y of maneuvers to enhance or block a single system, such as
ministration of prostaglandin analogs (misoprostol [31]) or
I to shift the eicosanoid balance from thromboxane produc-
2].
Unlike results in experimental animal models [9], our results
indicate that calcium channel blocking agents did not change
urinary ET excretion. Furthermore, despite effective blood pres-
sure and systemic vascular resistance reduction as previously
reported [33], no changes were apparent in glomerular filtration
or RVRI during the long-term studies reported here. These
results are supported by the failure of another dihydropyridine,
lacidipine, to alter daily surges in urinary ET excretion in renal
allograft recipients treated for a few weeks [34], although the
acute daily vasoconstriction after each CsA dose was blunted.
Hence, long-term renal vasoconstriction after transplantation is
not changed easily.
Do these changes in vasoactive regulatory mechanisms explain
the alterations in renal function after transplantation? Most
authors indicate that post-transplant reductions in GFR are
"hemodynamic" in nature, based on improvement in renal perfu-
sion and function develop after witholding CsA [35]. Conte et al
reported that the immediate decrements in renal blood flow and
GFR induced by CsA in normal human volunteers could be
reversed entirely by dopamine, lending support to this hypothesis
[361.
What relationship do these vasoactive systems have to long-
term renal parenchymal damage after transplantation? Our data
cannot address this issue directly, but raise important concerns. It
is recognized that irreversible changes in the kidney develop in
some transplant recipients [371. The basis for chronic CsA and
FK506 nephrotoxicity is not clear, and may involve multiple
mechanisms, including vascular and interstitial inflammatory or
fibrotic processes [37, 38]. Recent studies demonstrate that ET
exerts multiple actions on non-vascular cells, inducing mitogene-
sis, cytokine release and proliferation of fibroblasts [39—I The
possibility that long-term disturbances in endothelial function
with intrarenal release of ET may mediate permanent interstitial
4500
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Table 3. Effect of calcium channel blockers (CCBs) on endothelin (ET)
and prostacyclin (6-keto-PG-Fla)
CsA
group
(N = 44)
FK506
group(N 31)
Normal
subjects(N = 70)
Plasma ETpgIml
All patients 13.96 1.la 19.3 iT 7.07 1.0
CCB 14.50 1.4 17.4 3.0
No CCB 13.50 1.8 19.8 2.4a
Urinary ET ng/day
All patients 48 6' 57 8.8' 16.0 2.0
CCB 45±T 59±6a
No CCB 51 12 51 T
Urinary 6-keto-PG-Flci
ng/day
All patients 907 117 494 4Ø 2249 200
CCB 743 lOT 600 50"
No CCB 962 152" 450 ioo"
damage warrants serious consideration. Our results demonstrat-
ing persistent elevation of ET in both urine and plasma for two
years after non-renal transplantation with both CsA and FK506
based regimens support this possibility.
What is the role for pharmacological inhibition of endothelin
receptors in this disorder? Application of receptor antagonists
demonstrate at least two ET receptors which differ in tissue
distribution and effects [45, 461. Both ETa and ETh appear to be
present and participate in vasoconstriction within the kidney,
although this differs between species [241. Experimental studies
indicate that short-term CsA-induced reductions in GFR and
blood flow in the rat can be blocked by administration of
antibodies to endothelin [71or by administration of an antagonist
to the ETa receptor [7] Studies with other antagonists have not
found the same results consistently, although study conditions
differed [8]. The role of ET after human transplantation will be
examined most directly by administration of ET receptor antag-
onists. Recently, several nonpeptide antagonists have been syn-
thesized which may make orally active compounds available to
address this issue. None have been applied to humans as yet.
Preliminary data indicate that one such compound (Ro46-2005)
improves the outcomes of some forms of ischemic acute renal
failure, and subarachnoid hemorrhage [48], both of which have
been associated with increased endothelin levels. Based upon our
results demonstrating long-term increases in urinary endothelin,
we suggest that administration of endothelin antagonists offers the
potential to improve both early and late indices of renal function
after organ transplantation. Unlike essential hypertension in
which urinary excretion of endothelin is normal or reduced [49],
our results indicate that post-transplant elevations of both circu-
lating and urinary ET make it likely that clinically important
benefits may accrue from removing ET effects.
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